• Home
  • About Us

Idiopathic Pulmonary Fibrosis

Jeremy Feldman, MD

  • What is Idiopathic Pulmonary Fibrosis?
    • Idiopathic Pulmonary Fibrosis Definition
    • Symptoms of Idiopathic Pulmonary Fibrosis
    • Causes of Idiopathic Pulmonary Fibrosis
    • Who Gets Idiopathic Pulmonary Fibrosis
    • Gastro-Esophageal Reflux (GER) and Idiopathic Pulmonary Fibrosis
    • Interstitial Lung Disease vs. Idiopathic Pulmonary Fibrosis
    • Is Pulmonary Fibrosis Hereditary?
    • Research, Life Expectancy and Prognosis for Idiopathic Pulmonary Fibrosis
  • Diagnosing & Monitoring PF
    • Monitoring Progress of IPF
    • Idiopathic Pulmonary Fibrosis Diagnosis
    • Chest X-rays Used in IPF
    • CPET used in IPF
    • HRCT Scans Used to Evaluate IPF
    • Lung Biopsy To Diagnose IPF
    • Pulmonary Function Tests (PFTS)
    • Six Minute Walk Test To Monitor IPF
    • Stages of Idiopathic Pulmonary Fibrosis
    • Complications of Idiopathic Pulmonary Fibrosis
  • PF Treatment Options
    • Esbriet (pirfenidone) Used to Treat IPF
    • OFEV (nintedanib) Used to Treat IPF
    • Pulmonary Rehab for IPF Patients
    • Lung Transplantation for Pulmonary Fibrosis
    • Oxygen Used to Treat IPF
      • Update on Oxygen Use
    • Clinical Trials in Idiopathic Pulmonary Fibrosis
    • IPF & Leg Swelling
    • Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis
    • IPF Exacerbation
  • PF Advocacy & News
  • FAQ’s
    • Respiratory failure, NSIP, diet
    • Leg swelling, lung biopsy, side effects & pets
    • FAQ’s Enzyme Therapy, Progression of IPF & Oxygen
    • FAQ: Diarrhea, Fibrosis Reversal, IPF Symptoms
    • FAQ: Oxygen Flow, Anesthesia & Genetics
    • FAQ: Contagious Cough? Stem Cells, Familial IPF, Flying
    • FAQ: GERD, Fatigue & Environmental Exposure
    • FAQ: How to Travel to Your Doctor’s Office with Oxygen
    • FAQ: Lung Biopsy with Pulmonary Fibrosis
    • FAQ’s: Alcohol, Clinical Trials, Pulmonary Function Testing
    • FAQs: Emphysema, Exercise & Lung Biopsy

Causes of Idiopathic Pulmonary Fibrosis

Discussion about IPFAs the name implies, there is no clearly defined cause of Idiopathic Pulmonary Fibrosis.  However, over the past decade, scientists have begun to unravel the complex biologic underpinnings of the disease process.  The fibroblast has emerged as a major focus of attention.  In health, fibroblasts are responsible for maintaining the healthy framework of lung tissue.  In IPF there appears to be an exuberant production of supporting tissue that results in scar formation.  In contrast to other types of lung disease such as autoimmune lung diseases, inflammation appears to play a relatively minor role.

Within the lung tissue of IPF patients, there is dysregulation in mediators that signal proliferation.  This results in an exuberant scar response.  The precise cause of the disrupted signaling has not been well understood yet.  The epicenter of the scar forming process is the fibrotic foci.  These nests of cells appear to be responding to and generating disease amplifying signals.

A variety of genetic mutations have been identified in Idiopathic Pulmonary Fibrosis patients.  Surfactant proteins are required for normal lung function.  Abnormal surfactant has been seen in several families with familial IPF.  The DNA repair system called telomerases help prevent accumulating damage to the chromosomes.  Mutations in telomerase-related genes are associated with IPF.  The effect of ineffective DNA repair results in premature aging changes in the lungs.

Gastro-Esophageal Reflux (GER) has been associated with IPF and progression of IPF.  This suggests that periodic aspiration of gastric contents may incite or propagate lung injury that leads to scar formation.  There is a suggestion in the literature that treatment of GER may slow IPF progression.

There is no risk of transmitting IPF.  It is not contagious.  The vast majority of patients with IPF do not have a genetic or familial form of the disease.  This means that children and grandchildren are not likely to have the disease.

 

 

 

 

Featured Blog Posts

IPF CT Scan | Expiration-Supine

New Drugs Moving Forward for IPF

pulmonary fibrosis journey

Pulmonary Fibrosis Support: A Patient’s Story

Traveling with IPF

Traveling with Pulmonary Fibrosis

Recent Posts

  • Interstitial Lung Disease and Progressive Pulmonary Fibrosis
  • Pamrevlumab Ineffective in Treating IPF
  • New Drugs Moving Forward for IPF

Search by Keyword (Examples: GERD, Coughing, Traveling, etc.)

Search by Category

Popular Articles

IPF patient with doctor

Idiopathic Pulmonary Fibrosis Treatment Options

What is IPF?

  • What is Idiopathic Pulmonary Fibrosis?
    • Symptoms of Idiopathic Pulmonary Fibrosis
    • Causes of Idiopathic Pulmonary Fibrosis
    • Who Gets Idiopathic Pulmonary Fibrosis
    • Gastro-Esophageal Reflux (GER) and IPF
    • Interstitial Lung Disease vs. Idiopathic Pulmonary Fibrosis
    • Is Pulmonary Fibrosis Hereditary?
    • Research, Life Expectancy & Prognosis for Pulmonary Fibrosis

Diagnosing IPF

  • Idiopathic Pulmonary Fibrosis Diagnosis
    • Chest X-rays Used in IPF
    • CPET used in IPF
    • HRCT Scans Used to Evaluate IPF
    • Lung Biopsy To Diagnose IPF
    • Pulmonary Function Tests (PFTS)
    • Six Minute Walk Test To Monitor IPF
    • Stages of Idiopathic Pulmonary Fibrosis
    • Complications of Idiopathic Pulmonary Fibrosis

Treating IPF

  • Pulmonary Fibrosis Treatment Options
    • Esbriet (pirfenidone) Used to Treat IPF
    • OFEV (nintedanib) Used to Treat IPF
    • Pulmonary Rehab for IPF Patients
    • Lung Transplantation for Pulmonary Fibrosis
    • Oxygen Used to Treat IPF
    • Clinical Trials in Idiopathic Pulmonary Fibrosis
    • IPF & Leg Swelling
    • Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis
    • IPF Exacerbation

Disclaimer